{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:02:18Z","timestamp":1791266538283,"version":"4.1.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","award":["920528"],"award-info":[{"award-number":["920528"]}],"id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.micpath.2016.05.012","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T20:01:22Z","timestamp":1464120082000},"page":"38-44","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Immunization against HTLV-I with chitosan and tri-methylchitosan nanoparticles loaded with recombinant env23 and env13 antigens of envelope protein gp46"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8404-0816","authenticated-orcid":false,"given":"Maryam","family":"Amirnasr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1171-2452","authenticated-orcid":false,"given":"Tannan","family":"Fallah tafti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Sankian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdorrahim","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Tafaghodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.micpath.2016.05.012_bib1","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1016\/S0140-6736(98)09460-4","article-title":"Human T-lymphotropic virus type I infection","volume":"353","author":"Manns","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.micpath.2016.05.012_bib2","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jcv.2011.07.004","article-title":"High prevalence of HTLV-I infection in Mashhad, Northeast Iran: a population-based seroepidemiology survey","volume":"52","author":"Rafatpanah","year":"2011","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.micpath.2016.05.012_bib3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/138920306776359803","article-title":"Advances in HTLV-1 peptide vaccines and therapeutics","volume":"7","author":"Lynch","year":"2006","journal-title":"Curr. Protein Peptide Sci."},{"key":"10.1016\/j.micpath.2016.05.012_bib4","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S1473-3099(07)70081-6","article-title":"Human T-lymphotropic virus 1: recent knowledge about an ancient infection","author":"Verdonck","year":"2007","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.micpath.2016.05.012_bib5","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0264-410X(00)00340-6","article-title":"Enhanced immunogenicity of a conformational epitope of human T-lymphotropic virus type 1 using a novel chimeric peptide","volume":"19","author":"Frangione-Beebe","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2016.05.012_bib6","first-page":"6067","volume":"53","author":"Sherman","year":"1993","journal-title":"Cancer Res."},{"key":"10.1016\/j.micpath.2016.05.012_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0169-409X(01)00197-1","article-title":"Chitosan for mucosal vaccination","volume":"52","author":"Van der Lubben","year":"2001","journal-title":"Adv. drug Deliv. Rev."},{"key":"10.1016\/j.micpath.2016.05.012_bib8","doi-asserted-by":"crossref","first-page":"108","DOI":"10.2174\/156720108783954833","article-title":"Nasal immunization studies by cationic, fusogenic and cationic-fusogenic liposomes encapsulated with tetanus toxoid","volume":"5","author":"Tafaghodi","year":"2008","journal-title":"Curr. drug Deliv."},{"key":"10.1016\/j.micpath.2016.05.012_bib9","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2006.03.047","article-title":"Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN","volume":"319","author":"Tafaghodi","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.micpath.2016.05.012_bib10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3109\/10837450903479962","article-title":"Dextran microspheres could enhance immune responses against PLGA nanospheres encapsulated with tetanus toxoid and Quillaja saponins after nasal immunization in rabbit","volume":"16","author":"Mohaghegh","year":"2011","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.micpath.2016.05.012_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2014.08.032","article-title":"Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants","volume":"475","author":"Dehghan","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.micpath.2016.05.012_bib12","series-title":"Human T-lymphotropic Virus Type I: Virology, Pathogenesis, and Epidemiology","author":"Scadden","year":"2007"},{"key":"10.1016\/j.micpath.2016.05.012_bib13","doi-asserted-by":"crossref","first-page":"5341","DOI":"10.1016\/j.vaccine.2012.06.035","article-title":"Hepatitis B surface antigen nanoparticles coated with chitosan and trimethyl chitosan: impact of formulation on physicochemical and immunological characteristics","volume":"30","author":"Tafaghodi","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2016.05.012_bib14","first-page":"53","article-title":"Cloning, expression and purification of early secretory antigenic target 6kDa protein (ESAT-6) of Mycobacterium tuberculosis","volume":"3","author":"Farshadzadeh","year":"2007","journal-title":"Jundishapur J. Microbiol."},{"key":"10.1016\/j.micpath.2016.05.012_bib15","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.addr.2007.05.017","article-title":"Nanotechnology in vaccine delivery","volume":"60","author":"Peek","year":"2008","journal-title":"Adv. drug Deliv. Rev."},{"key":"10.1016\/j.micpath.2016.05.012_bib16","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/S0264-410X(99)00565-4","article-title":"Targeted expression of HTLV-I envelope proteins in muscle by DNA immunization of mice","volume":"18","author":"Armand","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2016.05.012_bib17","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1016\/j.vaccine.2005.04.021","article-title":"Effective nasal influenza vaccine delivery using chitosan","volume":"23","author":"Read","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2016.05.012_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jconrel.2005.11.014","article-title":"Preparation and characterization of protein-loaded N-trimethyl chitosan nanoparticles as nasal delivery system","volume":"111","author":"Amidi","year":"2006","journal-title":"J.\u00a0Control. Release"},{"key":"10.1016\/j.micpath.2016.05.012_bib19","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1016\/S0264-410X(01)00140-2","article-title":"Tetanus toxoid loaded \u2018preformed microspheres\u2019 of cross-linked dextran","volume":"19","author":"Diwan","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2016.05.012_bib20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1053\/beha.1999.0070","article-title":"Human T-lymphotropic virus type 1 infection","volume":"13","author":"Tsukasaki","year":"2000","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.micpath.2016.05.012_bib21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.progpolymsci.2006.06.001","article-title":"Chitin and chitosan: properties and applications","volume":"31","author":"Rinaudo","year":"2006","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.micpath.2016.05.012_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0928-0987(01)00172-5","article-title":"Chitosan and its derivatives in mucosal drug and vaccine delivery","volume":"14","author":"van der Lubben","year":"2001","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.micpath.2016.05.012_bib23","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.vaccine.2011.04.112","article-title":"Pharmaceutical and immunological evaluation of mucoadhesive nanoparticles based delivery system (s) administered intranasally","volume":"29","author":"Mangal","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.micpath.2016.05.012_bib24","first-page":"220","article-title":"Original Research Nano-adjuvanted polio vaccine: preparation and characterization of chitosan and trimethylchitosan (TMC) nanoparticles loaded with inactivated polio virus and coated with sodium alginate","volume":"1","author":"Tafaghodi","year":"2014","journal-title":"Nanomed. J."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088240101630078X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088240101630078X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T16:20:11Z","timestamp":1536682811000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088240101630078X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":24,"alternative-id":["S088240101630078X"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2016.05.012","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunization against HTLV-I with chitosan and tri-methylchitosan nanoparticles loaded with recombinant env23 and env13 antigens of envelope protein gp46","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2016.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}